Haloperidol package insert

Most SGAs differ from older medications pharmacologically in that serotonin 5HT2 receptor binding exceeds their affinity for dopamine D2 receptors, whereas in FGAs this is generally not the case. Largely for that reason, 5HT2 activity has been suggested as one basis for the lower overall risk of extrapyramidal side effects (EPS) with the atypical drugs compared with FGAs [ 5 ]. Other aspects of SGA pharmacology that correlate with reduced risk of EPS include "loose" D2 receptor binding with rapid dissociation rates [ 6 ] and preferential binding of drugs to receptors in limbic and cortical brain regions rather than striatal areas [ 7 ]. None of these hypotheses has been fully confirmed, and the most important message for the clinician is that the pharmacology of these drugs is complex and likely to result in some variability of side effect risk and pharmacokinetics from patient to patient.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

Haloperidol package insert

haloperidol package insert


haloperidol package inserthaloperidol package inserthaloperidol package inserthaloperidol package inserthaloperidol package insert